This Week in Pediatrics — Jun 10, 2026

Welcome to This Week in Pediatrics. This week we're covering 9 notable papers spanning advances in chronic disease management, key updates in prevention and public health, and a look at emerging diagnostic and therapeutic trends. Let's dive in.

We begin with chronic disease, looking at new insights from basic science to long-term clinical surveillance. In *Nature*, a study offers a potential new therapeutic target for inflammatory bowel disease [1]. Researchers identified a specific subset of regulatory CD8 T-cells guided by a receptor called GPR15. These cells appear to play a crucial role in controlling intestinal inflammation by killing activated macrophages. The study found that deleterious gene variants in GPR15 are associated with severe, early-onset IBD, and that these protective cells are reduced in the intestinal mucosa of patients with sporadic IBD. While still at the basic science stage, this discovery opens a new avenue for understanding organ-specific immune regulation in IBD. Moving from the bench to the bedside, a practical study in the *Journal of Pediatric Gastroenterology and Nutrition* evaluated bowel ultrasound as a non-invasive tool for managing children with moderate ulcerative colitis [2]. In a retrospective review of 77 patients, researchers found that an international scoring system, the IBUS-SAS, correlated well with endoscopic activity. An IBUS-SAS score of 49 or higher was an independent predictor of failing to achieve clinical remission and was associated with a more than four-fold increased odds of needing a colectomy within 12 months. The findings support using bowel ultrasound as a repeatable, radiation-free method to monitor disease and stratify risk in pediatric UC. Broadening our view of chronic care, a review in *JAMA* provides a critical overview of outcomes for survivors of cyanotic congenital heart disease [3]. The article focuses on the three most common types: Tetralogy of Fallot, D-loop transposition of the great arteries, and single-ventricle physiology requiring a Fontan procedure. While surgical interventions have made survival to adulthood common, these patients face significant long-term morbidity. For example, nearly all adults with repaired TOF develop right ventricular volume overload, and up to 45% have atrial arrhythmias by age 45. After an atrial switch operation for TGA, up to half of patients develop right ventricular dysfunction by age 25, with a risk of sudden cardiac death in up to 15%. Survival for Fontan patients can reach 50 to 80 percent at age 40, but is often complicated by progressive heart failure. The central message is the absolute necessity of life-long, multidisciplinary care involving both pediatric and adult congenital cardiologists, surgeons, and electrophysiologists to manage these inevitable late complications.

Next, we turn to prevention and public health, starting with a major success story in food allergy. A study in *JAMA Pediatrics* provides population-level evidence that updated infant feeding guidelines work [4]. Researchers in Australia compared the prevalence of egg allergy in infants before and after guidelines changed to recommend earlier egg introduction. Between the 2007-2011 cohort and the 2018-2019 cohort, the median age of egg introduction dropped from 8 months to 6 months. This shift was associated with a decrease in the adjusted prevalence of egg allergy from 9.2% down to 7.6%. The effect was even more dramatic in the highest-risk group—infants with early eczema—where prevalence plummeted from 34.6% to 21.9%. This study powerfully demonstrates that evidence-based guideline changes, when effectively implemented, can have a measurable impact on reducing the burden of food allergy. In contrast, a paper in *Pediatrics* highlights ongoing challenges in vaccine implementation, specifically for the rotavirus vaccine [5]. Analyzing data from the New Vaccine Surveillance Network, investigators identified key barriers to vaccination. The risk factors most strongly associated with not starting the series included receiving the first DTaP vaccine late, after 15 weeks of age, and being born extremely preterm. The guidelines that prohibit starting the series after 14 weeks and 6 days, and that recommend waiting until NICU discharge, create a difficult situation. The study found that over half of extremely preterm infants were not discharged from the NICU until after this 15-week cutoff, making them ineligible for the vaccine. The authors call for a re-evaluation of these guidelines, suggesting that allowing rotavirus vaccine administration in the NICU could remove a major barrier and improve coverage for this vulnerable population. Looking ahead, a policy paper in *The Lancet Global Health* argues for the proactive inclusion of young adolescents, aged 9 to 14, in the development of new tuberculosis vaccines [6]. While the current BCG vaccine loses efficacy after childhood, new vaccines are primarily being developed for older adolescents and adults. The authors argue that vaccinating the younger adolescent group offers a key opportunity to confer protection before the age-related rise in TB risk and before the acquisition of co-morbidities like HIV. However, they also acknowledge challenges, such as lower rates of TB case accrual in this age group, which makes traditional efficacy trials difficult. The paper proposes novel trial designs, such as focusing on household contacts of active TB cases, to generate the necessary data to support rapid implementation of new vaccines for this often-overlooked age group.

Our final theme covers new tools and emerging trends in pediatrics. From *Pediatric Research*, a study explores the feasibility of an automated, contactless radar system for outpatient motor surveillance in infants [7]. The technology uses frequency-modulated continuous-wave radar to record an infant's spontaneous movements for about 7 minutes. A pre-trained model then analyzes the movements for patterns like asymmetry or cramped-synchronized general movements to generate a risk score. While the initial model had only modest concordance with clinical classification, a simple within-cohort recalibration boosted concordance to 93%. The study also noted that an infant's clinical classification often changed between visits, highlighting the need for serial surveillance. A low-burden, privacy-preserving tool like this could make scalable, repeated assessment in the outpatient setting more feasible, helping to identify infants at risk for motor delay earlier. Turning to therapeutics, a major trial in *The New England Journal of Medicine* adds a new agent to the obesity treatment landscape, with clear implications for pediatrics [8]. The study evaluated survodutide, a dual glucagon and GLP-1 receptor agonist, in adults with obesity but without diabetes. In this phase 3 trial, participants receiving weekly injections of survodutide for 76 weeks had a mean weight reduction of 12 to 13 percent, compared to about 5 percent in the placebo group, which also received lifestyle counseling. As expected with this class of medication, gastrointestinal side effects were very common, affecting over 80 percent of participants on the drug, though they were typically mild to moderate. While this trial was in adults, its results are a significant development in a therapeutic area of intense interest for managing adolescent obesity. Finally, a brief report in *Pediatrics* serves as a cautionary note on how media and regulatory announcements can influence prescribing patterns [9]. The authors describe the context around leucovorin, or folinic acid. In 2025, the FDA expanded its label to include cerebral folate deficiency, an extremely rare neurologic condition that shares some symptoms with autism spectrum disorder. This announcement was accompanied by a high-profile White House press conference touting its use for ASD, and was preceded by national media reports on its potential benefits. The authors note they are measuring the changes in leucovorin prescriptions during this period of heightened attention, highlighting a real-world example of how political and media focus, rather than robust clinical trial data for a specific indication, can create pressure and interest around off-label use.

If you only have time for one paper this week, make it the study on egg allergy in *JAMA Pediatrics* [4]. It provides compelling, real-world, population-level data confirming that the advice we give parents about early allergen introduction is making a tangible difference in reducing the prevalence of one of the most common food allergies.

Here are the key takeaways from this week in Pediatrics. First, for infants, especially those with eczema, recommend introducing well-cooked egg around 6 months of age, as this has been shown to significantly reduce the population prevalence of egg allergy. Second, in managing pediatric ulcerative colitis, consider using bowel ultrasound with the IBUS-SAS score as a non-invasive tool to monitor disease activity and help predict the need for colectomy. Third, be vigilant about the rotavirus vaccine schedule for preterm infants; the 15-week cutoff for the first dose means many infants discharged late from the NICU are ineligible, highlighting a critical gap in our current guidelines. Fourth, ensure that all survivors of cyanotic congenital heart disease are engaged in lifelong, multidisciplinary specialty care to proactively manage the high risk of late complications like arrhythmias and heart failure. And finally, keep an eye on emerging technologies like contactless radar for motor surveillance, which may soon offer a new way to perform serial neurodevelopmental screening in the clinic.

That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.